140 related articles for article (PubMed ID: 17545613)
1. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
Tatetsu H; Ueno S; Hata H; Yamada Y; Takeya M; Mitsuya H; Tenen DG; Okuno Y
Cancer Res; 2007 Jun; 67(11):5328-36. PubMed ID: 17545613
[TBL] [Abstract][Full Text] [Related]
2. PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL.
Ueno S; Tatetsu H; Hata H; Iino T; Niiro H; Akashi K; Tenen DG; Mitsuya H; Okuno Y
Oncogene; 2009 Nov; 28(46):4116-25. PubMed ID: 19749795
[TBL] [Abstract][Full Text] [Related]
3. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
[TBL] [Abstract][Full Text] [Related]
4. PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer element.
Bonadies N; Neururer Ch; Steege A; Vallabhapurapu S; Pabst T; Mueller BU
Oncogene; 2010 Feb; 29(7):1062-72. PubMed ID: 19966852
[TBL] [Abstract][Full Text] [Related]
5. PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
Yuki H; Ueno S; Tatetsu H; Niiro H; Iino T; Endo S; Kawano Y; Komohara Y; Takeya M; Hata H; Okada S; Watanabe T; Akashi K; Mitsuya H; Okuno Y
Blood; 2013 Feb; 121(6):962-70. PubMed ID: 23212521
[TBL] [Abstract][Full Text] [Related]
6. Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.
Nojima M; Maruyama R; Yasui H; Suzuki H; Maruyama Y; Tarasawa I; Sasaki Y; Asaoku H; Sakai H; Hayashi T; Mori M; Imai K; Tokino T; Ishida T; Toyota M; Shinomura Y
Clin Cancer Res; 2009 Jul; 15(13):4356-64. PubMed ID: 19549772
[TBL] [Abstract][Full Text] [Related]
7. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1.
Rosenbauer F; Owens BM; Yu L; Tumang JR; Steidl U; Kutok JL; Clayton LK; Wagner K; Scheller M; Iwasaki H; Liu C; Hackanson B; Akashi K; Leutz A; Rothstein TL; Plass C; Tenen DG
Nat Genet; 2006 Jan; 38(1):27-37. PubMed ID: 16311598
[TBL] [Abstract][Full Text] [Related]
8. The proximal promoter of the human cathepsin G gene conferring myeloid-specific expression includes C/EBP, c-myb and PU.1 binding sites.
Lennartsson A; Garwicz D; Lindmark A; Gullberg U
Gene; 2005 Aug; 356():193-202. PubMed ID: 16019164
[TBL] [Abstract][Full Text] [Related]
9. High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma.
Song YF; Xu R; Zhang XH; Chen BB; Chen Q; Chen YM; Xie Y
J Clin Pathol; 2006 Sep; 59(9):947-51. PubMed ID: 16489177
[TBL] [Abstract][Full Text] [Related]
10. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
[TBL] [Abstract][Full Text] [Related]
11. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
12. PU.1/Spi-1 is essential for the B cell-specific activity of the mouse CD72 promoter.
Ying H; Chang JF; Parnes JR
J Immunol; 1998 Mar; 160(5):2287-96. PubMed ID: 9498769
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.
Tshuikina M; Jernberg-Wiklund H; Nilsson K; Oberg F
Exp Hematol; 2008 Dec; 36(12):1673-1681. PubMed ID: 18922617
[TBL] [Abstract][Full Text] [Related]
14. A xenograft model reveals that PU.1 functions as a tumor suppressor for multiple myeloma in vivo.
Nishimura N; Endo S; Ueno S; Ueno N; Tatetsu H; Hirata S; Hata H; Komohara Y; Takeya M; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2017 May; 486(4):916-922. PubMed ID: 28347818
[TBL] [Abstract][Full Text] [Related]
15. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor.
Torlakovic E; Malecka A; Myklebust JH; Tierens A; Aasheim HC; Nesland JM; Smeland E; Kvaløy S; Delabie J
J Pathol; 2005 Jul; 206(3):312-9. PubMed ID: 15892171
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma.
Chim CS; Pang R; Fung TK; Choi CL; Liang R
Leukemia; 2007 Dec; 21(12):2527-36. PubMed ID: 17882284
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
[TBL] [Abstract][Full Text] [Related]
18. Potential autoregulation of transcription factor PU.1 by an upstream regulatory element.
Okuno Y; Huang G; Rosenbauer F; Evans EK; Radomska HS; Iwasaki H; Akashi K; Moreau-Gachelin F; Li Y; Zhang P; Göttgens B; Tenen DG
Mol Cell Biol; 2005 Apr; 25(7):2832-45. PubMed ID: 15767686
[TBL] [Abstract][Full Text] [Related]
19. Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b.
Suzuki M; Yamada T; Kihara-Negishi F; Sakurai T; Hara E; Tenen DG; Hozumi N; Oikawa T
Oncogene; 2006 Apr; 25(17):2477-88. PubMed ID: 16331260
[TBL] [Abstract][Full Text] [Related]
20. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.
Loddenkemper C; Anagnostopoulos I; Hummel M; Jöhrens-Leder K; Foss HD; Jundt F; Wirth T; Dörken B; Stein H
J Pathol; 2004 Jan; 202(1):60-9. PubMed ID: 14694522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
